The hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2–) subtype, which is characterized by the expression of estrogen receptor (ER) and/or progesterone receptor (PR) without HER2 overexpression/amplification, accounts for approximately 70% of breast cancer patients. Here, ESR1 is linked to breast cancer.